Rare disease has moved beyond a science-led opportunity into a strategy-led one. As more programmes reach the clinic and regulatory frameworks mature, the advantage is shifting toward companies that ...

We are standing at an inflection point, where scientific progress and patient-centered care are converging to fundamentally transform the Alzheimer’s disease landscape. Breakthroughs are evolving the ...